Crowley Susan T, Chertow Glenn M, Vitale Joseph, O'Connor Theresa, Zhang Jane, Schein Roland M H, Choudhury Devasmita, Finkel Kevin, Vijayan Anitha, Paganini Emil, Palevsky Paul M
Renal Section (111F), VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA.
Clin J Am Soc Nephrol. 2008 Jul;3(4):955-61. doi: 10.2215/CJN.05621207. Epub 2008 Apr 2.
Design elements of clinical trials can introduce recruitment bias and reduce study efficiency. Trials involving the critically ill may be particularly prone to design-related inefficiencies.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Enrollment into the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study was systematically monitored. Reasons for nonenrollment into this study comparing strategies of renal replacement therapy in critically ill patients with acute kidney injury were categorized as modifiable or nonmodifiable.
4339 patients were screened; 2744 fulfilled inclusion criteria. Of these, 1034 were ineligible by exclusion criteria. Of the remaining 1710 patients, 1124 (65.7%) enrolled. Impediments to informed consent excluded 21.4% of potentially eligible patients. Delayed identification of potential patients, physician refusal, and involvement in competing trials accounted for 4.4, 2.7, and 2.3% of exclusions. Comfort measures only status, chronic illness, chronic kidney disease, and obesity excluded 11.8, 7.8, 7.6, and 5.9% of potential patients. Modification of an enrollment window reduced the loss of patients from 6.6 to 2.3%.
The Acute Renal Failure Trial Network Study's enrollment efficiency compared favorably with previous intensive care unit intervention trials and supports the representativeness of its enrolled population. Impediments to informed consent highlight the need for nontraditional acquisition methods. Restrictive enrollment windows may hamper recruitment but can be effectively modified. The low rate of physician refusal acknowledges clinical equipoise in the study design. Underlying comorbidities are important design considerations for future trials that involve the critically ill with acute kidney injury.
临床试验的设计要素可能会导致招募偏倚并降低研究效率。涉及危重症患者的试验可能特别容易出现与设计相关的低效率情况。
设计、地点、参与者与测量方法:对退伍军人事务部/国立卫生研究院急性肾衰竭试验网络研究的入组情况进行了系统监测。将急性肾损伤危重症患者肾替代治疗策略比较研究中未入组的原因分为可改变因素和不可改变因素。
共筛查了4339例患者;2744例符合纳入标准。其中,1034例因排除标准而不符合条件。在其余1710例患者中,1124例(65.7%)入组。知情同意的障碍排除了21.4%的潜在合格患者。潜在患者识别延迟、医生拒绝以及参与竞争性试验分别占排除原因的4.4%、2.7%和2.3%。仅采取舒适措施、慢性病、慢性肾病和肥胖分别排除了11.8%、7.8%、7.6%和5.9%的潜在患者。调整入组窗口使患者流失率从6.6%降至2.3%。
急性肾衰竭试验网络研究的入组效率优于以往的重症监护病房干预试验,并支持其入组人群的代表性。知情同意的障碍凸显了采用非传统获取方法的必要性。限制性的入组窗口可能会妨碍招募,但可以有效调整。医生拒绝率较低表明研究设计中存在临床 equipoise。潜在的合并症是未来涉及急性肾损伤危重症患者试验的重要设计考虑因素。